Amgen Inc
NASDAQ:AMGN
Amgen Inc
Operating Income
Amgen Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$9.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
Moderna Inc
NASDAQ:MRNA
|
Operating Income
-$4.2B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is Amgen Inc's Operating Income?
Operating Income
8.2B
USD
Based on the financial report for Dec 31, 2023, Amgen Inc's Operating Income amounts to 8.2B USD.
What is Amgen Inc's Operating Income growth rate?
Operating Income CAGR 10Y
3%
Over the last year, the Operating Income growth was -19%. The average annual Operating Income growth rates for Amgen Inc have been -4% over the past three years , -5% over the past five years , and 3% over the past ten years .